Enzo Biochem, Inc. (NYSE:ENZ) Short Interest Update

Enzo Biochem, Inc. (NYSE:ENZ) was the recipient of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 433,000 shares, a decrease of 9.3% from the October 31st total of 477,500 shares. Approximately 1.2% of the company’s stock are short sold. Based on an average trading volume of 86,700 shares, the days-to-cover ratio is presently 5.0 days.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Enzo Biochem in a report on Sunday. They set a “hold” rating on the stock.

Enzo Biochem Stock Performance

Enzo Biochem stock remained flat at $1.07 during mid-day trading on Tuesday. The company’s stock had a trading volume of 231,783 shares, compared to its average volume of 101,569. Enzo Biochem has a 1-year low of $0.93 and a 1-year high of $1.50. The firm’s 50-day moving average is $1.11 and its two-hundred day moving average is $1.11.

Enzo Biochem Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 2nd. Stockholders of record on Friday, November 15th were given a dividend of $0.10 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $0.40 dividend on an annualized basis and a dividend yield of 37.38%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. XTX Topco Ltd lifted its position in shares of Enzo Biochem by 94.5% during the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after buying an additional 13,735 shares in the last quarter. BBR Partners LLC acquired a new position in Enzo Biochem in the 3rd quarter valued at $112,000. Geode Capital Management LLC raised its stake in Enzo Biochem by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after purchasing an additional 11,742 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Enzo Biochem by 2.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after purchasing an additional 64,417 shares during the last quarter. Hedge funds and other institutional investors own 36.90% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.